SuperworthAurinia Pharmaceuticals EPS AUPH
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- $2.29
- Latest quarter, Q2 FY26
- $0.28
- +75% on a year earlier
- Fiscal year 2025
- $2.08
- +4060% on the year before
Aurinia Pharmaceuticals' earnings per share was $2.29 over the twelve months to Jun 30, 2026, up 433% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.28, up 75% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $2.08 | +4060% |
| FY2024 | $0.05 | n/a |
| FY2023 | −$0.54 | n/a |
| FY2022 | −$0.76 | n/a |
| FY2021 | −$1.41 | n/a |
| FY2020 | −$0.86 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.28 | +75% | $2.29 | |
| Q1 FY26 | $0.25 | +56% | $2.17 | |
| Q4 FY25 | $1.53 | +15200% | $2.08 | |
| Q3 FY25 | $0.23 | +130% | $0.56 | |
| Q2 FY25 | $0.16 | +1500% | $0.43 | |
| Q1 FY25 | $0.16 | n/a | $0.28 | |
| Q4 FY24 | $0.01 | n/a | $0.05 | |
| Q3 FY24 | $0.10 | n/a | −$0.15 | |
| Q2 FY24 | $0.01 | n/a | −$0.34 | |
| Q1 FY24 | −$0.07 | n/a | −$0.43 | |
| Q4 FY23 | −$0.19 | n/a | −$0.54 | |
| Q3 FY23 | −$0.09 | n/a | −$0.53 |
Against its peers
Companies in Drug Manufacturers - General nearest Aurinia Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AUPHAurinia Pharmaceuticals | $2.29 | +433% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aurinia Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.